Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

NCT04393493

Cardiorenal Syndrome

COMPLETED PHASE2

Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

NCT06203236

Acute Heart Failure Chronic Kidney Diseases

NOT_YET_RECRUITING PHASE4

Spironolactone in Patients With Single Ventricle Heart

NCT00211081

Congenital Disorders

COMPLETED NA

Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment

NCT05411991

Acute Heart Failure Diuretics Drug Reactions

COMPLETED PHASE4

Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study

NCT04465123

Acute Heart Failure Acute Kidney Injury

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiorenal Syndrome Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Experimental, randomized, double-blind, and prospective study

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultrasound Guided Treatment

Patients allocated to this will be guided (diuretic treatment) by ultrasound (VExUS) findings

Group Type EXPERIMENTAL

Diuretic de/escalation based on ultrasound findings (VExUS Score)

Intervention Type OTHER

Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)

Clinical Guided Treatment

Patients allocated to this will be guided (diuretic treatment) by clinical congestion score (CCS) findings

Group Type ACTIVE_COMPARATOR

Diuretic de/escalation based on clinical findings (CCS Score)

Intervention Type OTHER

Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diuretic de/escalation based on ultrasound findings (VExUS Score)

Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)

Intervention Type OTHER

Diuretic de/escalation based on clinical findings (CCS Score)

Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old or older
* Type 1 cardiorenal syndrome in emergency room at Instituto Nacional de Cardiologia Ignacio Chávez

Exclusion Criteria

* Patients who denied to participate
* Liver disease (cirrohsis)
* Complex congenital heart disease
* Kidney transplant
* Heart transplant
* Severe valvular disease
* Chronic kidney disease KDIGO G5 and G5d
* INTERMACS Score 2

Eligible Sex

ALL

Accepts Healthy Volunteers

No